Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
NCT ID: NCT06780475
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
15 participants
OBSERVATIONAL
2025-05-27
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
NCT03783078
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
NCT03684785
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
NCT02267603
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
NCT03747484
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
NCT03304639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
* Informed for the study and no-opposed for participation;
* Affiliated with a social security scheme or in an equivalent situation.
Exclusion Criteria
* Patients under guardianship or trusteeship;
* Pregnancy or breastfeed;
* Patients refusal.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astrid Blom, MD
Role: PRINCIPAL_INVESTIGATOR
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Yassine Taoufik, MD, PhD
Role: STUDY_DIRECTOR
U1186 INSERM, PAUL BROUSSE Hospital, APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Boulogne-Billancourt, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A00643-44
Identifier Type: REGISTRY
Identifier Source: secondary_id
APHP240470
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.